Valero SLM, Jaramillo RM, Cruz RJ, Tejeda RM, Labardini J, Cervera CE, Enriquez CV, Cruz VL, Salles MT

Language: Spanish
References: 16
Page: 79-83
PDF size: 81.58 Kb.

ABSTRACT

To make the chronic eosinophilic leukemia one should exclude the presence of other hematologic neoplasias. The blastic transformation is brought about in some patients in unspecified evolution time. Case. 21-year old patient; his clinical frame: affected by erythematous, prurigilous macular, with eosinophilia in peripheral blood and bone marrow with evolution to cardiac insufficiency. He’s administered imatinib with secondary myelosuppression. Chromosome numerical alteration and specifically chromosome 16 deletion in q22 is observed through FISH. Conclusion. Hematological neoplasias associated with t (5:12) (q33, p13) and variants PDGFRB lead to myeloid disorders. The blastic transformation can even appear up to 24 years after the eosinophilia. Gen FGFR1, which is located in chromosome 8p11 produces a myeoloproliferative syndrome with eosionophilia and chronic eosinophilic leukemia with evolution to blastic phase. The chromosomic alterations and the following evolution to blastic phase found in this patient, who was treated with imatinib, could be the starting point for respective additional research.

REFERENCES

1. Brain B. The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. Haematologica 2004; 89: 236-7.

2. Finella BB. The eosinophilias, including the idiopathic hypereosinophilic syndrome. B J Haematol 2003; 121: 203-23.

3. Animesh P, Terra R, Luis FP, Ching Yang Li, Henry D, Tazelaar E, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391-7.

4. Tefferi, Ayelew MD. Blood eosinophilia: A new paradigm in disease classification, Diagnosis and treatment. Mayo Clinic Proceedings 2005; 80(1): 75-83.

5. Tracy IG, Arber DlA. Pathology of the myeloproliferative diseases. Hematology/oncology clinics of North America 2003; Vol 17 Number 5.

6. Jason G, Jan Cools, James M, Stanley L, Schrier D, Gary G, et al. The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-91.

7. P Vandenberghe, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004; 18: 734-42.

8. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83(10): 2759-79.

9. Gerald JG, Kristin ML, Animesh P, Ayalew T, Joseph HB. Treatment of hypereosinophilic syndrome with imatinib mesilate. The Lancet 2002; 359: 1577-8.

10. Garrett JK, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113: 115-19.

11. Weide R, Rieder H, Mehraein Y, Wolf M, Kaiser U, Seifart U, Gora C. Chronic eosinophilic leukaemia: a distinct myeloproliferative disease. B J Haematol 1997; 96(1): 117-23.

12. Frickhofen N. et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol 2004; 83: 477-80.

13. Medina J, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leucemia in chronic phase. Cancer 2003; 98: 1905-11.

14. Barbara JB. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. B J Haematol 2003; 122: 173-9.

15. Von Bubnoff, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19: 286-7.

16. Martha W, Daniel J, De Angelo, James DG, Richard M. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2005; 105: 22-30.